Source: c19study.com

The studies continue to roll out, and there has been very positive results in pre and post exposure as well as early treatment of confirmed COVID-19 patients ( near 100%). There is also considerable efficacy (62%) when treating late. Most studies concur.

Check out c19study.com for the up to date tally on what is evolving. The site is live and constantly updated.
blank

Check out c19study.com for the up to date tally on what is evolving. The site is live and constantly updated.




See Related:
Hydroxychloroquine significantly lowers COVID-19 death rate, Henry Ford Health study finds

NY Study: Risk Factors for Mortality in Patients with COVID-19 in New York City

Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection.

Electrocardiographic safety of daily Hydroxychloroquine 400mg plus Azithromycin 250mg as an ambulatory treatment for COVID-19 patients in Cameroon.

Global Research: Media Sabotage of Hydroxychloroquine Use for COVID-19; Doctors Worldwide Protest the Disaster

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »